These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 21835218

  • 1. DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge.
    Lu YC, Li MC, Chen YM, Chu CY, Lin SF, Yang WJ.
    Vaccine; 2011 Oct 13; 29(44):7740-6. PubMed ID: 21835218
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model.
    Chiang CH, Huang WF, Huang LP, Lin SF, Yang WJ.
    Vaccine; 2009 Jul 23; 27(34):4565-70. PubMed ID: 19520199
    [Abstract] [Full Text] [Related]

  • 3. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA.
    Shin SJ, Bae JL, Cho YW, Lee DY, Kim DH, Yang MS, Jang YS, Yoo HS.
    FEMS Immunol Med Microbiol; 2005 Feb 01; 43(2):155-64. PubMed ID: 15681145
    [Abstract] [Full Text] [Related]

  • 4. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.
    Seo KW, Kim SH, Park J, Son Y, Yoo HS, Lee KY, Jang YS.
    Vet Immunol Immunopathol; 2013 Jan 15; 151(1-2):102-12. PubMed ID: 23200821
    [Abstract] [Full Text] [Related]

  • 5. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
    Shin MK, Kang ML, Jung MH, Cha SB, Lee WJ, Kim JM, Kim DH, Yoo HS.
    Vet Immunol Immunopathol; 2013 Jan 15; 151(1-2):132-9. PubMed ID: 23206402
    [Abstract] [Full Text] [Related]

  • 6. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
    Maas A, Meens J, Baltes N, Hennig-Pauka I, Gerlach GF.
    Vaccine; 2006 Nov 30; 24(49-50):7226-37. PubMed ID: 17027123
    [Abstract] [Full Text] [Related]

  • 7. Selection of serotype-specific vaccine candidate genes in Actinobacillus pleuropneumoniae and heterologous immunization with Propionibacterium acnes.
    Lei L, Sun C, Lu S, Feng X, Wang J, Han W.
    Vaccine; 2008 Nov 18; 26(49):6274-80. PubMed ID: 18835316
    [Abstract] [Full Text] [Related]

  • 8. Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia.
    Sadilkova L, Nepereny J, Vrzal V, Sebo P, Osicka R.
    Vet Res; 2012 Jan 12; 43(1):2. PubMed ID: 22240397
    [Abstract] [Full Text] [Related]

  • 9. Adhesion protein ApfA of Actinobacillus pleuropneumoniae is required for pathogenesis and is a potential target for vaccine development.
    Zhou Y, Li L, Chen Z, Yuan H, Chen H, Zhou R.
    Clin Vaccine Immunol; 2013 Feb 12; 20(2):287-94. PubMed ID: 23269417
    [Abstract] [Full Text] [Related]

  • 10. Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria.
    Lee KY, Kim DH, Kang TJ, Kim J, Chung GH, Yoo HS, Arntzen CJ, Yang MS, Jang YS.
    FEMS Immunol Med Microbiol; 2006 Dec 12; 48(3):381-9. PubMed ID: 17054716
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
    Bei W, He Q, Zhou R, Yan L, Huang H, Chen H.
    Vet Microbiol; 2007 Nov 15; 125(1-2):120-7. PubMed ID: 17580102
    [Abstract] [Full Text] [Related]

  • 12. Construction and immune effect of Haemophilus parasuis DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in mice.
    Fu S, Zhang M, Ou J, Liu H, Tan C, Liu J, Chen H, Bei W.
    Vaccine; 2012 Nov 06; 30(48):6839-44. PubMed ID: 23000128
    [Abstract] [Full Text] [Related]

  • 13. Identification of proteins of Propionibacterium acnes for use as vaccine candidates to prevent infection by the pig pathogen Actinobacillus pleuropneumoniae.
    Li L, Sun C, Yang F, Yang S, Feng X, Gu J, Han W, Langford PR, Lei L.
    Vaccine; 2013 Oct 25; 31(45):5269-75. PubMed ID: 24051157
    [Abstract] [Full Text] [Related]

  • 14. Oral immunization of mice with Saccharomyces cerevisiae expressing a neutralizing epitope of ApxIIA exotoxin from Actinobacillus pleuropneumoniae induces systemic and mucosal immune responses.
    Shin MK, Lee WJ, Jung MH, Cha SB, Shin SW, Yoo A, Kim DH, Yoo HS.
    Microbiol Immunol; 2013 Jun 25; 57(6):417-25. PubMed ID: 23773020
    [Abstract] [Full Text] [Related]

  • 15. Characterization of antigenic determinants in ApxIIA exotoxin capable of inducing protective immunity to Actinobacillus pleuropneumoniae challenge.
    Seo KW, Kim DH, Kim AH, Yoo HS, Lee KY, Jang YS.
    Immunol Invest; 2011 Jun 25; 40(5):465-80. PubMed ID: 21425909
    [Abstract] [Full Text] [Related]

  • 16. [Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA].
    Liu J, Chen Y, Hu L, Bei W, Chen H.
    Sheng Wu Gong Cheng Xue Bao; 2010 Mar 25; 26(3):305-10. PubMed ID: 20518341
    [Abstract] [Full Text] [Related]

  • 17. Nasal immunization with M cell-targeting ligand-conjugated ApxIIA toxin fragment induces protective immunity against Actinobacillus pleuropneumoniae infection in a murine model.
    Park J, Seo KW, Kim SH, Lee HY, Kim B, Lim CW, Kim JH, Yoo HS, Jang YS.
    Vet Microbiol; 2015 May 15; 177(1-2):142-53. PubMed ID: 25818577
    [Abstract] [Full Text] [Related]

  • 18. Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae.
    Wang C, Wang Y, Shao M, Si W, Liu H, Chang Y, Peng W, Kong X, Liu S.
    Vaccine; 2009 Sep 25; 27(42):5816-21. PubMed ID: 19654060
    [Abstract] [Full Text] [Related]

  • 19. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.
    Xu F, Chen X, Shi A, Yang B, Wang J, Li Y, Guo X, Blackall PJ, Yang H.
    Vet Microbiol; 2006 Dec 20; 118(3-4):230-9. PubMed ID: 16930871
    [Abstract] [Full Text] [Related]

  • 20. Nasal immunization with mannan-decorated mucoadhesive HPMCP microspheres containing ApxIIA toxin induces protective immunity against challenge infection with Actinobacillus pleuropneumoiae in mice.
    Li HS, Shin MK, Singh B, Maharjan S, Park TE, Kang SK, Yoo HS, Hong ZS, Cho CS, Choi YJ.
    J Control Release; 2016 Jul 10; 233():114-25. PubMed ID: 27189136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.